Search research articles
Contact Us
Filters
Showing results (11-20 of 18) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 18 results.
Case Reports in Hepatology
|
July 11, 2015
Acute Liver Toxicity due to Efavirenz/Emtricitabine/Tenofovir
Rashmee Patil, Mel A Ona, Haris Papafragkakis, et al.
Alimentary Pharmacology & Therapeutics
|
April 6, 2026
Review Article: An Update on Non-Invasive Tests for Steatotic Liver Disease - Insights From the ESSENCE Phase 3 Trial and Longitudinal Studies
Naim Alkhouri, Naga Chalasani, Zobair Younossi, et al.
The American Journal of Gastroenterology
|
August 12, 2021
Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease
Stephen A Harrison, Seth J Baum, Nadege T Gunn, et al.
JHEP Reports : Innovation in Hepatology
|
January 16, 2023
A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis
Stephen A Harrison, Peter J Ruane, Bradley Freilich, et al.
Nature Medicine
|
July 9, 2021
Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial
Stephen A Harrison, Peter J Ruane, Bradley L Freilich, et al.
The New England Journal of Medicine
|
May 9, 2025
Efruxifermin in Compensated Liver Cirrhosis Caused by MASH
Mazen Noureddin, Mary E Rinella, Naga P Chalasani, et al.
The New England Journal of Medicine
|
February 7, 2024
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
Stephen A Harrison, Pierre Bedossa, Cynthia D Guy, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD
|
December 26, 2025
Diagnostic Performance of LIVERFASt as a Non-invasive Liver Fibrosis Test: Data from Three Cohorts of Patients with Metabolic Dysfunction-associated Steatotic Liver Disease
Naim Alkhouri, Parvez Mantry, Humberto C Gonzalez, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 18) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 18 results.
Case Reports in Hepatology
|
July 11, 2015
Acute Liver Toxicity due to Efavirenz/Emtricitabine/Tenofovir
Rashmee Patil, Mel A Ona, Haris Papafragkakis, et al.
Alimentary Pharmacology & Therapeutics
|
April 6, 2026
Review Article: An Update on Non-Invasive Tests for Steatotic Liver Disease - Insights From the ESSENCE Phase 3 Trial and Longitudinal Studies
Naim Alkhouri, Naga Chalasani, Zobair Younossi, et al.
The American Journal of Gastroenterology
|
August 12, 2021
Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease
Stephen A Harrison, Seth J Baum, Nadege T Gunn, et al.
JHEP Reports : Innovation in Hepatology
|
January 16, 2023
A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis
Stephen A Harrison, Peter J Ruane, Bradley Freilich, et al.
Nature Medicine
|
July 9, 2021
Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial
Stephen A Harrison, Peter J Ruane, Bradley L Freilich, et al.
The New England Journal of Medicine
|
May 9, 2025
Efruxifermin in Compensated Liver Cirrhosis Caused by MASH
Mazen Noureddin, Mary E Rinella, Naga P Chalasani, et al.
The New England Journal of Medicine
|
February 7, 2024
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
Stephen A Harrison, Pierre Bedossa, Cynthia D Guy, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD
|
December 26, 2025
Diagnostic Performance of LIVERFASt as a Non-invasive Liver Fibrosis Test: Data from Three Cohorts of Patients with Metabolic Dysfunction-associated Steatotic Liver Disease
Naim Alkhouri, Parvez Mantry, Humberto C Gonzalez, et al.
Page
of 2